Table 1. Risk factors identified by IRR prediction model using the CLL11 data set.
| Risk factor | ORa | 95% CIa | Significance retained with bootstrapping (10 000 simulations; %) | |
|---|---|---|---|---|
| Randomization | Obinutuzumab versus rituximab | 8.4 | 5.2–13.4 | 100 |
| CD20 MFIb expressed on CLL cells at baseline | 3.5 | 1.9–6.7 | 98 | |
| CD16 MFIb on NK (CD56+CD16+) gated cells at baseline | 3.2 | 1.5–6.8 | 97 | |
| Baseline neutrophil countb (x109/l) | 0.31 | 0.15–0.63 | 87 | |
| FcγRIIIA genotype (position 158) | FV versus FF | 1.8 | 1.1–2.8 | 80 (overall) |
| FcγRIIIA genotype (position 158) | VV versus FF | 2.3 | 1.1–5.2 | |
| Splenomegaly (as measured by physical examination in cm below costal margin) | 1.1 | 1.01–1.15 | 84 | |
| Baseline ALCb (x109/l) | 1.8 | 1.03–3.0 | 65 | |
| Presence of respiratory co-morbidity | Yes/no | 1.7 | 1.07–2.7 | 73 |
Abbreviations: ALC, absolute lymphocyte count; CI, confidence interval; CLL, chronic lymphocytic lymphoma; IRR, infusion-related reaction; MFI, mean fluorescence intensity; NK, natural killer; OR, odds ratio.
a
>1 implies increased risk, <1 implies reduced risk for increasing values of risk factor.
b
Variables were log transformed before modeling.